Bristol Myers Squibb's Dividend Appeal Amidst GLP-1 Hype
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy BMY?
Source: NASDAQ.COM
- Dividend Yield Advantage: Bristol Myers Squibb offers a 4% dividend yield, significantly higher than the S&P 500's 1.1% and the pharmaceutical sector's average of 1.7%, making it an attractive option for income-seeking investors, especially during market volatility.
- Market Competition and Opportunities: While GLP-1 weight-loss drugs are currently in the spotlight, Bristol Myers Squibb remains focused on developing cardiovascular, cancer, and immune-related medications, highlighting the company's strategic diversification in important healthcare sectors.
- Attractive Price Correction: The company's stock is approximately 25% below its late 2022 highs, providing investors with an opportunity to benefit from potential price recovery while enjoying a high dividend yield, thereby enhancing its investment appeal.
- Patent Protection and R&D Outlook: Although the Opdivo cancer drug will lose patent protection in 2028, Bristol Myers Squibb is exploring new delivery methods to extend its patent life, alongside other drugs in the development pipeline, demonstrating the company's capability to manage patent expirations and its commitment to ongoing innovation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 61.100
Low
37.00
Averages
55.86
High
68.00
Current: 61.100
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bristol Myers Squibb: A High Dividend Investment Opportunity
- Dividend Yield Advantage: Bristol Myers Squibb currently offers a 4% dividend yield, significantly higher than the S&P 500's 1.1% and the pharmaceutical sector's average of 1.7%, making it an attractive option for income-seeking investors.
- Market Competition and Opportunities: Despite operating in a highly competitive pharmaceutical market, Bristol Myers Squibb focuses on cardiovascular, cancer, and immune-related drugs, which present substantial market potential, especially as GLP-1 weight-loss drugs gain attention.
- Price Recovery Potential: With a current stock price of $62.37, approximately 25% below its late 2022 highs, there is recovery potential for investors, and the company's 70% payout ratio indicates a solid commitment to maintaining dividends.
- Patent Protection and Growth Foundation: While Bristol Myers Squibb's Opdivo cancer drug will lose patent protection in 2028, the company is developing alternative delivery methods to extend its patent life, and its pipeline includes other drugs, showcasing its ongoing growth potential.
See More
FourWorld Capital Increases Stake in Sable Offshore Corp.
- Increased Holdings: FourWorld Capital Management LLC acquired 8,105,608 shares of Sable Offshore Corp. in Q4 2025, valued at $73.11 million, making it the fund's largest holding at 62.89% of AUM.
- Stock Performance: As of February 27, 2026, Sable Offshore shares were priced at $8.25, down 72.92% over the past year, significantly underperforming the S&P 500 by 86.44 percentage points, indicating severe competitiveness issues in the market.
- Legal Challenges: Sable Offshore faces major legal hurdles; despite federal approval for the restart of its Las Flores pipeline in California, environmental groups filed lawsuits to halt it, and a recent court ruling against the company could increase stock volatility.
- Investment Risks: While the significant drop in Sable Offshore's stock price makes it a relatively cheap investment, its future success will heavily depend on resolving ongoing legal issues, categorizing it as a high-risk buy at this time.
See More
FourWorld Capital Management Acquires Major Stake in Sable Offshore Corp.
- New Investment Position: According to a February 17, 2026 SEC filing, FourWorld Capital Management acquired 8,105,608 shares of Sable Offshore Corp. valued at $73.11 million, making it the fund's largest holding at 62.9% of reportable AUM.
- Portfolio Structure Shift: As of December 31, 2025, Sable Offshore's holding value of $73.11 million significantly overshadows other holdings, with IWM and BMY making up less than 5%, indicating FourWorld's strong conviction in this investment.
- Stock Volatility Risk: As of February 27, 2026, Sable Offshore shares were priced at $8.25, down 72.92% over the past year, facing legal challenges that could increase future stock volatility, necessitating cautious risk assessment by investors.
- Legal Challenges Impact: Although Sable Offshore received federal approval to restart its Las Flores pipeline in California, lawsuits from environmental groups and a judge's ruling against the restart hinder progress, with ongoing legal battles likely to directly affect the company's operations and stock performance.
See More
Middle East Turmoil Triggers Market Panic
- Oil Price Surge Impact: The closure of the Strait of Hormuz due to U.S. and Israeli attacks on Iran has led to skyrocketing oil prices, which are expected to exacerbate inflation and hinder the Federal Reserve's ability to cut interest rates, posing significant obstacles to economic recovery.
- Private Equity Crisis: Private equity and private credit firms are facing a trust crisis as they are perceived as high-risk debt bearers, leading to a sharp decline in market confidence regarding their future, which could result in a wave of bankruptcies and further heighten recession risks.
- Nvidia Under Customer Pressure: Despite Nvidia reporting strong quarterly results last week, concerns over future demand have intensified as competitors Amazon and Alphabet launched cheaper chips, causing its stock price to drop from $196 to $176, reflecting investor panic in the tech sector.
- Layoff Wave Triggers Market Turmoil: Block's announcement of a 40% workforce reduction has sparked concerns about the future of the tech industry; while this move may boost stock prices in the short term, it risks losing top talent and undermining operational stability and market confidence in the long run.
See More
Bristol Myers Squibb's Dividend Appeal Amidst GLP-1 Hype
- Dividend Yield Advantage: Bristol Myers Squibb offers a 4% dividend yield, significantly higher than the S&P 500's 1.1% and the pharmaceutical sector's average of 1.7%, making it an attractive option for income-seeking investors, especially during market volatility.
- Market Competition and Opportunities: While GLP-1 weight-loss drugs are currently in the spotlight, Bristol Myers Squibb remains focused on developing cardiovascular, cancer, and immune-related medications, highlighting the company's strategic diversification in important healthcare sectors.
- Attractive Price Correction: The company's stock is approximately 25% below its late 2022 highs, providing investors with an opportunity to benefit from potential price recovery while enjoying a high dividend yield, thereby enhancing its investment appeal.
- Patent Protection and R&D Outlook: Although the Opdivo cancer drug will lose patent protection in 2028, Bristol Myers Squibb is exploring new delivery methods to extend its patent life, alongside other drugs in the development pipeline, demonstrating the company's capability to manage patent expirations and its commitment to ongoing innovation.
See More
Bristol Myers Squibb: A High Dividend Investment Opportunity
- Dividend Yield Advantage: Bristol Myers Squibb currently offers a 4% dividend yield, significantly higher than the S&P 500's 1.1% and the pharmaceutical sector's average of 1.7%, making it an attractive option for income-seeking investors.
- Market Competition and Opportunities: Despite the fierce competition and high costs of drug development in the pharmaceutical industry, Bristol Myers Squibb's focus on cardiovascular, cancer, and immune-related medicines presents significant market opportunities, especially as GLP-1 weight-loss drugs capture investor attention.
- Stock Price Pullback and Recovery Potential: The company's stock is approximately 25% below its late 2022 highs, providing investors with an opportunity to benefit from potential price recovery while enjoying a high dividend yield, with a payout ratio of 70% that is not overly concerning.
- Patent Expiration and Development Outlook: While Bristol Myers Squibb's Opdivo cancer drug will lose patent protection in 2028, the company is exploring alternative delivery methods to extend patent protections, and its development pipeline includes other drugs, demonstrating its capability to manage patent expirations effectively.
See More
Bristol Myers Squibb: A High Dividend Investment Opportunity
- Dividend Yield Advantage: Bristol Myers Squibb currently offers a 4% dividend yield, significantly higher than the S&P 500's 1.1% and the pharmaceutical sector's average of 1.7%, making it an attractive option for income-seeking investors.
- Market Competition and Opportunities: Despite operating in a highly competitive pharmaceutical market, Bristol Myers Squibb focuses on cardiovascular, cancer, and immune-related drugs, which present substantial market potential, especially as GLP-1 weight-loss drugs gain attention.
- Price Recovery Potential: With a current stock price of $62.37, approximately 25% below its late 2022 highs, there is recovery potential for investors, and the company's 70% payout ratio indicates a solid commitment to maintaining dividends.
- Patent Protection and Growth Foundation: While Bristol Myers Squibb's Opdivo cancer drug will lose patent protection in 2028, the company is developing alternative delivery methods to extend its patent life, and its pipeline includes other drugs, showcasing its ongoing growth potential.
See More
FourWorld Capital Increases Stake in Sable Offshore Corp.
- Increased Holdings: FourWorld Capital Management LLC acquired 8,105,608 shares of Sable Offshore Corp. in Q4 2025, valued at $73.11 million, making it the fund's largest holding at 62.89% of AUM.
- Stock Performance: As of February 27, 2026, Sable Offshore shares were priced at $8.25, down 72.92% over the past year, significantly underperforming the S&P 500 by 86.44 percentage points, indicating severe competitiveness issues in the market.
- Legal Challenges: Sable Offshore faces major legal hurdles; despite federal approval for the restart of its Las Flores pipeline in California, environmental groups filed lawsuits to halt it, and a recent court ruling against the company could increase stock volatility.
- Investment Risks: While the significant drop in Sable Offshore's stock price makes it a relatively cheap investment, its future success will heavily depend on resolving ongoing legal issues, categorizing it as a high-risk buy at this time.
See More
FourWorld Capital Management Acquires Major Stake in Sable Offshore Corp.
- New Investment Position: According to a February 17, 2026 SEC filing, FourWorld Capital Management acquired 8,105,608 shares of Sable Offshore Corp. valued at $73.11 million, making it the fund's largest holding at 62.9% of reportable AUM.
- Portfolio Structure Shift: As of December 31, 2025, Sable Offshore's holding value of $73.11 million significantly overshadows other holdings, with IWM and BMY making up less than 5%, indicating FourWorld's strong conviction in this investment.
- Stock Volatility Risk: As of February 27, 2026, Sable Offshore shares were priced at $8.25, down 72.92% over the past year, facing legal challenges that could increase future stock volatility, necessitating cautious risk assessment by investors.
- Legal Challenges Impact: Although Sable Offshore received federal approval to restart its Las Flores pipeline in California, lawsuits from environmental groups and a judge's ruling against the restart hinder progress, with ongoing legal battles likely to directly affect the company's operations and stock performance.
See More
Middle East Turmoil Triggers Market Panic
- Oil Price Surge Impact: The closure of the Strait of Hormuz due to U.S. and Israeli attacks on Iran has led to skyrocketing oil prices, which are expected to exacerbate inflation and hinder the Federal Reserve's ability to cut interest rates, posing significant obstacles to economic recovery.
- Private Equity Crisis: Private equity and private credit firms are facing a trust crisis as they are perceived as high-risk debt bearers, leading to a sharp decline in market confidence regarding their future, which could result in a wave of bankruptcies and further heighten recession risks.
- Nvidia Under Customer Pressure: Despite Nvidia reporting strong quarterly results last week, concerns over future demand have intensified as competitors Amazon and Alphabet launched cheaper chips, causing its stock price to drop from $196 to $176, reflecting investor panic in the tech sector.
- Layoff Wave Triggers Market Turmoil: Block's announcement of a 40% workforce reduction has sparked concerns about the future of the tech industry; while this move may boost stock prices in the short term, it risks losing top talent and undermining operational stability and market confidence in the long run.
See More
Bristol Myers Squibb's Dividend Appeal Amidst GLP-1 Hype
- Dividend Yield Advantage: Bristol Myers Squibb offers a 4% dividend yield, significantly higher than the S&P 500's 1.1% and the pharmaceutical sector's average of 1.7%, making it an attractive option for income-seeking investors, especially during market volatility.
- Market Competition and Opportunities: While GLP-1 weight-loss drugs are currently in the spotlight, Bristol Myers Squibb remains focused on developing cardiovascular, cancer, and immune-related medications, highlighting the company's strategic diversification in important healthcare sectors.
- Attractive Price Correction: The company's stock is approximately 25% below its late 2022 highs, providing investors with an opportunity to benefit from potential price recovery while enjoying a high dividend yield, thereby enhancing its investment appeal.
- Patent Protection and R&D Outlook: Although the Opdivo cancer drug will lose patent protection in 2028, Bristol Myers Squibb is exploring new delivery methods to extend its patent life, alongside other drugs in the development pipeline, demonstrating the company's capability to manage patent expirations and its commitment to ongoing innovation.
See More
Bristol Myers Squibb: A High Dividend Investment Opportunity
- Dividend Yield Advantage: Bristol Myers Squibb currently offers a 4% dividend yield, significantly higher than the S&P 500's 1.1% and the pharmaceutical sector's average of 1.7%, making it an attractive option for income-seeking investors.
- Market Competition and Opportunities: Despite the fierce competition and high costs of drug development in the pharmaceutical industry, Bristol Myers Squibb's focus on cardiovascular, cancer, and immune-related medicines presents significant market opportunities, especially as GLP-1 weight-loss drugs capture investor attention.
- Stock Price Pullback and Recovery Potential: The company's stock is approximately 25% below its late 2022 highs, providing investors with an opportunity to benefit from potential price recovery while enjoying a high dividend yield, with a payout ratio of 70% that is not overly concerning.
- Patent Expiration and Development Outlook: While Bristol Myers Squibb's Opdivo cancer drug will lose patent protection in 2028, the company is exploring alternative delivery methods to extend patent protections, and its development pipeline includes other drugs, demonstrating its capability to manage patent expirations effectively.
See More
